DOI:
10.1055/s-00044881
Journal of Laboratory Physicians
LinksClose Window
References
Lubner SJ, Mahoney MR, Kolesar JL. et al.
Report of a multicenter phase II trial testing a combination of biweekly bevacizumab and daily erlotinib in patients with unresectable biliary cancer: a phase II Consortium study.
J Clin Oncol 2010;
28 (21) 3491-3497
Access:
Access:
We do not assume any responsibility for the contents of the web pages of other providers.